Skip to main content

Verona Pharma plc

VRNADelisted Oct 7, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001657312

Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.

13F holders, Q2 2024

Institutional positions in Verona Pharma plc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
125
+13 vs. Q1 2024
Shares held
66.2M
−775.6K (−1.2%) vs. Q1 2024
Total value
$957.0M
−$127.9M (−11.8%) vs. Q1 2024
New holders
26
44 more added
Sold out
13
33 more reduced

1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting VRNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2024: 125 institutions
Q1 2021: 37 institutionsQ2 2021: 37 institutionsQ3 2021: 40 institutionsQ4 2021: 42 institutionsQ1 2022: 39 institutionsQ2 2022: 40 institutionsQ3 2022: 68 institutionsQ4 2022: 88 institutionsQ1 2023: 95 institutionsQ2 2023: 105 institutionsQ3 2023: 102 institutionsQ4 2023: 117 institutionsQ1 2024: 113 institutionsQ2 2024: 125 institutionsQ3 2024: 150 institutionsQ4 2024: 191 institutionsQ1 2025: 258 institutionsQ2 2025: 292 institutionsQ3 2025: 243 institutionsQ4 2025: 1 institutionQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ2 2024: $957.0M
Q1 2021: $305.1MQ2 2021: $239.9MQ3 2021: $202.7MQ4 2021: $248.0MQ1 2022: $181.7MQ2 2022: $145.9MQ3 2022: $529.0MQ4 2022: $1.31BQ1 2023: $1.21BQ2 2023: $1.33BQ3 2023: $1.07BQ4 2023: $1.35BQ1 2024: $1.08BQ2 2024: $957.0MQ3 2024: $1.95BQ4 2024: $3.19BQ1 2025: $4.58BQ2 2025: $7.18BQ3 2025: $8.57BQ4 2025: $359.0KQ1 2026: $0Q2 2026: $0
Institutions holding VRNA and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20251$359.0K
Q3 2025243$8.57B
Q2 2025292$7.18B
Q1 2025258$4.58B
Q4 2024191$3.19B
Q3 2024150$1.95B
Q2 2024125$957.0M
Q1 2024113$1.08B
Q4 2023117$1.35B
Q3 2023102$1.07B
Q2 2023105$1.33B
Q1 202395$1.21B
Q4 202288$1.31B
Q3 202268$529.0M
Q2 202240$145.9M
Q1 202239$181.7M
Q4 202142$248.0M
Q3 202140$202.7M
Q2 202137$239.9M
Q1 202137$305.1M

Institutions, Q2 2024

Shares, value and share of portfolio for each institution holding Verona Pharma plc; share changes are against Q1 2024.

Institutions holding VRNA in Q2 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Candriam Luxembourg S.C.A.772,997$11.2M0.07%+772,997New
Boothbay Fund Management, LLC855,398$12.4M0.40%+216,280+33.8%Added
Morgan Stanley864,031$12.5M0.00%+530,859+159.3%Added
American Century Companies Inc878,043$12.7M0.01%+317,184+56.6%Added
Rice Hall James & Associates, LLC939,576$13.6M0.81%+263,819+39.0%Added
Price T Rowe Associates Inc949,375$13.7M0.00%+949,375New
Laurion Capital Management LP1,050,842$15.2M0.50%+168,802+19.1%Added
Hood River Capital Management LLC1,062,456$15.4M0.32%+74,700+7.6%Added
Janus Henderson Group PLC1,092,042$15.8M0.01%−939,952−46.3%Reduced
Aisling Capital Management LP1,115,352$16.1M6.98%00.0%Unchanged
Jennison Associates LLC1,128,032$16.3M0.01%−465,801−29.2%Reduced
Bellevue Group AG1,134,229$16.4M0.27%−5,066−0.4%Reduced
Wellington Management Group LLP1,571,360$22.7M0.00%−2,338,106−59.8%Reduced
Caligan Partners LP1,843,756$26.7M6.23%+547,309+42.2%Added
Octagon Capital Advisors LP1,895,200$27.4M4.52%−473,800−20.0%Reduced
Federated Hermes, Inc.2,163,600$31.3M0.07%−95,000−4.2%Reduced
Perceptive Advisors LLC2,433,725$35.2M0.85%−1,327,851−35.3%Reduced
Carlyle Group Inc.2,457,500$35.5M3.37%00.0%Unchanged
OrbiMed Advisors LLC2,861,801$41.4M0.88%−536,266−15.8%Reduced
Maverick Capital LtdSuperinvestorMaverick Capital3,092,807$44.7M0.85%+1,316,998+74.2%Added
Frazier Life Sciences Management, L.P.3,314,349$47.9M2.24%+300,000+10.0%Added
Vivo Capital, LLC3,549,758$51.3M4.74%−60,419−1.7%Reduced
Deep Track Capital, LP4,000,000$57.8M1.73%+812,585+25.5%Added
NEA Management Company, LLC5,584,753$80.8M6.08%+476,190+9.3%Added
Ra Capital Management, L.P.7,632,646$110.4M1.46%+1,314,656+20.8%Added
First Turn Management, LLC0$00.00%−973,130−100.0%Sold out
Ally Bridge Group (NY) LLC0$00.00%−736,738−100.0%Sold out
AXA S.A.0$00.00%−277,784−100.0%Sold out
Superstring Capital Management LP0$00.00%−259,383−100.0%Sold out
Polar Asset Management Partners Inc.0$00.00%−96,500−100.0%Sold out
UBS Oconnor LLC0$00.00%−36,305−100.0%Sold out
Bank of New York Mellon Corp0$00.00%−29,676−100.0%Sold out
Capstone Investment Advisors, LLC0$00.00%−25,616−100.0%Sold out
Virtu Financial LLC0$00.00%−23,180−100.0%Sold out
Cubist Systematic Strategies, LLC0$00.00%−13,682−100.0%Sold out
Quantbot Technologies LP0$00.00%−2,458−100.0%Sold out
CoreCap Advisors, LLC0$00.00%−657−100.0%Sold out
Zurcher Kantonalbank (Zurich Cantonalbank)0$00.00%−2−100.0%Sold out
Cutler Group LP––––Not filed